Swathi Parvataneni
Child & Adolescent Psychiatry · Shreveport, LANPI 1881079028
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 230 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 17.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,367, 3.7 times the $367 reported in 2019. Among child & adolescent psychiatry clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 230 payments — averaging $19.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$771
- Neurocrine Biosciences, Inc.$627
- Teva Pharmaceuticals USA, Inc.$550
- Johnson & Johnson$467
- Lundbeck LLC$411
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$381
- plus $1K from 11 others
What the payments were for
- Food & beverage$4,386100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 54 | $771 |
| Neurocrine Biosciences, Inc. | 21 | $627 |
| Teva Pharmaceuticals USA, Inc. | 32 | $550 |
| Johnson & Johnson | 18 | $467 |
| Lundbeck LLC | 20 | $411 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 21 | $381 |
| Alkermes, Inc. | 15 | $291 |
| Otsuka America Pharmaceutical, Inc. | 14 | $252 |
| Braeburn Inc. | 8 | $147 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $134 |
| Sunovion Pharmaceuticals Inc. | 8 | $113 |
| Livanova USA, Inc. | 2 | $74 |
| E.r. Squibb & Sons, L.L.C. | 3 | $66 |
| Axsome Therapeutics, Inc. | 2 | $35 |
| Vanda Pharmaceuticals Inc. | 1 | $25 |
| Bioxcel Therapeutics, Inc. | 1 | $24 |
| Ironshore Pharmaceuticals Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$250
How this compares
$4,386 in reported general payments places this provider in the 90th percentile of 70 child & adolescent psychiatry providers in Louisiana.
See all child & adolescent psychiatry providers in Louisiana →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lisinopril | 12 | $110 |
Paid to pharmacies, not to this prescriber.
Other child & adolescent psychiatry in Shreveport
- Manish SaranShreveport$11K
- Sadaf JavaidShreveport$4K
- Katherine SmithShreveport$3K
- Keerthiga RaveendranShreveport$3K
- Hannah ScottShreveport$162
- John WagnerShreveport$153
- McLeod GwynetteShreveport$139
- Jason WuttkeNew Orleans$11K
- Nicholas LavinLafayette$6K
- Mark SandsMetairie$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.